Muutke küpsiste eelistusi

E-raamat: IGA Nephropathy: From Molecules to Men.

, Series edited by
  • Formaat - PDF+DRM
  • Hind: 74,88 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

The author of this volume has studied IgA nephropathy for nearly 25 years, almost as long as primary IgA nephropathy has been recognized as a new disease. IgA nephropathy, considered to be an immune-complex-mediated glomerulonephri tis, is characterized by granular deposition of IgA (mainly IgA1) and C3 in the glomerular mesangial areas and is defined as nephropathy showing pro- liferative changes in the glomerular mesangial cells and increases in the mesangial matrices. Apart from being one of the most common types of chronic glomerulonephritis, it is also the most frequent case of end-stage renal disease. Since the pathogenesis of IgA nephropathy is still obscure, specific treatment is not yet available. Previous approaches have included tonsillectomy, anticoagulants, prednisolone, immunosuppressants, angiotensin-converting enzyme inhibitors and others. During his career, the author of this book has studied many aspects of IgA nephropathy, shedding much light on the mechanism of development and progression of this disease. He also undertook new treatments for patients and developed animal models for IgA nephropathy. The purpose of the present volume is to review the authors work on pathogenesis and treatment of the disease and to provide the most up-to-date findings on this subject, constituting a valuable source of information for nephrologists, general practitioners, residents and interns.